Considerations for Successful Treatment-free Remission

Stuart L. Goldberg, Michael Savona, Michael J. Mauro

Conclusions and Future Directions

Approximately 40% to 60% of those patients with CML-CP, who achieve sustained (≥ 2 years) deep molecular response (DMR) with TKI therapy, can achieve TFR. Molecular relapses typically occurred within 6 months, and patients quickly regained their prior depth of MR upon retreatment with the same TKI. As such, many TFR trials require monthly RQ-PCR monitoring for the first 6 to 12 months, with a gradual reduction in frequency thereafter. Clinical progression of CML related to participation in a TFR study has been observed only once, although fear of progression could limit patient participation in trials.

http://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(17)30991-6/fulltext